Sinil Pharmaceutical Co Stock Total Asset
| 012790 Stock | KRW 6,600 10.00 0.15% |
Sinil Pharmaceutical Co fundamentals help investors to digest information that contributes to Sinil Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Sinil Stock. The fundamental analysis module provides a way to measure Sinil Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sinil Pharmaceutical stock.
Sinil |
Sinil Pharmaceutical Co Company Total Asset Analysis
Sinil Pharmaceutical's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Sinil Pharmaceutical Total Asset | 128.97 B |
Most of Sinil Pharmaceutical's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sinil Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Sinil Pharmaceutical Co has a Total Asset of 128.97 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The total asset for all Republic of Korea stocks is significantly lower than that of the firm.
Sinil Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sinil Pharmaceutical's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sinil Pharmaceutical could also be used in its relative valuation, which is a method of valuing Sinil Pharmaceutical by comparing valuation metrics of similar companies.Sinil Pharmaceutical is currently under evaluation in total asset category among its peers.
Sinil Fundamentals
| Return On Equity | 9.59 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 159.61 B | |||
| Shares Outstanding | 7.5 M | |||
| Shares Owned By Insiders | 40.12 % | |||
| Shares Owned By Institutions | 0.58 % | |||
| Price To Earning | 15.03 X | |||
| Price To Sales | 1.00 X | |||
| Revenue | 61.75 B | |||
| Gross Profit | 24.2 B | |||
| EBITDA | 9.46 B | |||
| Net Income | 6.68 B | |||
| Cash And Equivalents | 7.31 B | |||
| Total Debt | 139.48 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 4.96 X | |||
| Cash Flow From Operations | 11.16 B | |||
| Target Price | 20300.0 | |||
| Number Of Employees | 13 | |||
| Beta | 1.85 | |||
| Market Capitalization | 62.74 B | |||
| Total Asset | 128.97 B | |||
| Retained Earnings | 75.63 B | |||
| Working Capital | 41.08 B | |||
| Current Asset | 50.02 B | |||
| Current Liabilities | 8.94 B | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 128.97 B |
About Sinil Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sinil Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinil Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinil Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Sinil Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sinil Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sinil Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Sinil Stock
| 0.9 | 102940 | Kolon Life Science | PairCorr |
| 0.91 | 074430 | Aminologics CoLtd | PairCorr |
| 0.63 | 023910 | Daihan Pharmaceutical | PairCorr |
The ability to find closely correlated positions to Sinil Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sinil Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sinil Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sinil Pharmaceutical Co to buy it.
The correlation of Sinil Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sinil Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sinil Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sinil Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Sinil Stock
Sinil Pharmaceutical financial ratios help investors to determine whether Sinil Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sinil with respect to the benefits of owning Sinil Pharmaceutical security.